225Ac与213Bi标记的P物质类似物用于胶质瘤治疗
本文综述了靶向α治疗用于复发胶质母细胞瘤的进展,采用瘤内注射213Bi-DOTA-物质P或225Ac-DOTAGA-物质P。GBM细胞NK-1受体高表达且肿瘤新生血管亦强表达,可同时靶向血管与肿瘤结构。研究者发起的I/II期研究显示该疗法与标准治疗相比具有优势,但尚无大型对照系列。
要点
- GBM细胞NK-1受体高表达且不依赖恶性程度,肿瘤新生血管亦强表达NK-1受体。
- 瘤内注射213Bi-DOTA-物质P或225Ac-DOTAGA-物质P已进入复发GBM治疗武器库。
- 研究者发起的I/II期研究中该靶向α治疗与标准治疗相比具有优势,但尚无大型对照系列。
核心结论
- 靶向α治疗使用213Bi/225Ac标记的物质P在研究者发起的I/II期研究中与标准治疗相比具有优势,局限在于迄今尚无大型对照系列。
研究设计与样本
- 综述,总结靶向α治疗用于恶性胶质瘤的研究者发起I期和II期研究。
主要发现
- GBM细胞中NK-1表达增高非常普遍,且与恶性程度无关。
- NK-1受体系统不仅表达于癌细胞膜,肿瘤新生血管内亦强表达,提示可同时靶向血管与肿瘤结构。
- 基于放射物理性质,α发射体比β发射金属放射性核素更具前景。
- 研究者发起的I/II期研究中,213Bi/225Ac标记物质P的靶向α治疗与标准治疗相比具有优势,但尚无大型对照系列。
临床怎么用
- 复发GBM可考虑瘤内注射213Bi-DOTA-物质P或225Ac-DOTAGA-物质P进行靶向α治疗(作者认为该疗法已进入治疗武器库)。
局限性
- 迄今尚无大型对照系列。
- 进一步开发应聚焦于改善化合物的生物学和化学性质,以及通过专用导管系统给药以改善放射性药物在胶质瘤生长与浸润区内的瘤内分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Within the last decades, there has been no major improvement in treatment of patients with glioma, especially with glioblastoma multiforme (GBM) which is related to specific features of this tumor type, such as heterogeneity at the macroscopic, microscopic and genetic level, the infiltrative nature of tumors and the obstacle of the brain-blood barrier which limits the accessability of most drugs. The current standard of care is surgical resection, followed by radio- and chemotherapy. After first-line treatment of the primary lesion, tumor recurrence is diagnosed in virtually all GBM patients. Treatment of tumor recurrence represents a challenging clinical task. Surgical resection to relief symptoms of mass effect and/or salvage chemotherapy are often considered as last therapeutic option. A new treatment option is urgently needed. Targeted alpha therapy with an intratumoral injection of 213Bi-DOTA-Substance P (SP) or 225Ac-DOTAGA-Substance P has been introduced into the therapeutic armamentarium of recurrent GBM. There are many advantages of using SP such as very high prevalence of increased NK-1 expression in GBM cells, regardless of the degree of malignancy, and expression of the NK-1 receptor system not only on the membrane of cancer cells but also strong expression of NK1 receptors within the tumor neovasculature suggesting concomitant targeting of vascular and neoplastic structures. Radioisotopes with different physical properties, mainly beta-emitting metallic radionuclides, were implemented for brain tumor treatment. Based on their radiophysical properties, however, alpha emitters exhibit more promising properties. In investigator-initiated phase I and II studies, targeted alpha therapy using Bi-213/Ac-225 radiolabeled Substance P for malignant gliomas compare favorably with standard therapy, with the limitation that no large controlled series have so far been generated. Further development should focus on the improvement of the biological and chemical properties of the compound and the application by dedicated catheter systems to improve the intratumoral distribution of the radiopharmaceutical within growth and infiltrative zone of these glial neoplasms.
引用
- Królicki L, Kunikowska J, Bruchertseifer F, et al. 225Ac- and 213Bi-Substance P Analogues for Glioma Therapy. Semin Nucl Med. 2020. PMID: 32172799. doi:10.1053/j.semnuclmed.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。